Endonovo Therapeutics (ENDVD) Stock Price, News & Analysis

Company Overview

Endonovo Therapeutics, Inc. is a biotechnology company, which engages in the development of bio-electronic approach to regenerative medicine. The firm also develops, manufactures and distributes evolutionary medical devices focused on the healing of wounds and reduction of pain, edema and inflammation on and in the human body. Its technology and products include Electroceuticals, EFECT Trial, SofPulse, Electroceutical Therapy, and Scientific Studies. The company was founded in November 2008 and is headquartered in Woodland Hills, CA.

Key Stats

• Today's Range: N/A
• 50-Day Range: N/A
• 52-Week Range: N/A
• Volume: 10,030 shs
• Average Volume: 11,850 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

ENDVD Stock Analysis - Frequently Asked Questions

How do I buy shares of Endonovo Therapeutics?

Shares of ENDVD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Pharmaceutical Preparations
• Sub-Industry: Medical Equipment
• Current Symbol: OTCMKTS:ENDVD
• CIK: N/A
• Web: endonovo.com
• Phone: (800) 489-4774
• Fax: N/A
• Employees: 147,000
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$400 thousand
• Net Margins: -6,075.54%
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: -279.35%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: $170 thousand
• Price / Sales: 0.00
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($0.59) per share
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 1,227,000
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: 1.98